Clinical trials: Grade III Glioma
High Grade Glioma, Astrocytoma, Grade III
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
This is a Phase 2 study of newly diagnosed patients with high grade glioma (HGG) undergoing standard radiation therapy and temozolomide treatment.
- Conditions
- High Grade Glioma, Astrocytoma, Grade III, Glioblastoma
- Trial name
- BMX-HGG (NCT02655601)
- Testing
- BMX-001, Radiation Therapy, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 177 people
- Sponsor
- BioMimetix JV, LLC
Malignant Glioma
Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas
The aim of the present Phase III study is to assess the positive predictive value of NPC-07 (5-aminolevulinic acid hydrochloride) induced tissue fluorescence, safety and pharmacokinetics following a single dose of NPC-07 orally…
- Trial name
- NCT01167322
- Testing
- NPC-07 for oral administration
- Where
- 3 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Nobelpharma
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and…
- Trial name
- NCT05765812
- Testing
- Zedoresertib, Temozolomide, Radiotherapy
- Where
- 16 sites in United States, Spain and 1 more
- Volunteers
- 116 people
- Sponsor
- Debiopharm International SA
Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after…
- Trial name
- STELLAR (NCT02796261)
- Testing
- Eflornithine, Lomustine
- Where
- 79 sites in United States, Belgium and 6 more
- Volunteers
- 343 people
- Sponsor
- Orbus Therapeutics, Inc.
Glioblastoma Multiforme, Anaplastic Oligoastrocytoma
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT02026271
- Testing
- Ad-RTS-hIL-12, veledimex
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Alaunos Therapeutics
Glioblastoma Multiforme, Glioblastoma
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma
- Trial name
- GBM (NCT00045968)
- Testing
- Dendritic cell immunotherapy
- Where
- 86 sites in United States, Canada and 2 more
- Volunteers
- 348 people
- Sponsor
- Northwest Biotherapeutics
Glioblastoma
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma.
- Trial name
- INTELLANCE-2 (NCT02343406)
- Testing
- Depatuxizumab mafodotin, Temozolomide, Lomustine
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 266 people
- Sponsor
- AbbVie
NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic
First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor
This is a phase 1, multicentre, first-in-human, open-label, dose-escalation/consolidation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered JBI-778 in EGFR mutated…
- Conditions
- NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic, Adenoid Cystic Carcinoma of the Head and Neck
- Trial name
- NCT07755397
- Testing
- JBI-778
- Where
- 6 sites in India
- Volunteers
- 30 people
- Sponsor
- Jubilant Therapeutics India Limited
Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma
Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
This is a 2-part multicenter Phase 1b study designed to test icapamespib in patients with recurrent brain lesions. Part 1 of the trial will be a standard 3 by 3 dose escalation design where different doses are examined.
- Conditions
- Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma, Grade 3 or 4 Astrocytoma, Glioblastoma Surgery
- Trial name
- Glio (NCT04782609)
- Testing
- Icapamespib
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Samus Therapeutics, Inc.
Low-grade Glioma, Pediatric Low-grade Gliomas
FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration
An open-label, randomized, multi-center phase III clinical study: Aim to evaluate the efficacy and safety of FCN-159 monotherapy versus the treatment by investigator's choice in patients with pediatric low-grade glioma harboring…
- Conditions
- Low-grade Glioma, Pediatric Low-grade Gliomas, pLGG With BRAF Alteration
- Trial name
- NCT07004075
- Testing
- Luvometinib, Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Expanded Access to ANG1005 for Individual Patients
This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient…
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis
- Trial name
- NCT02755987
- Testing
- ANG1005
- Where
- 2 sites in United States
- Sponsor
- Angiochem Inc
Glioma of Brain
Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse
Open label, non-randomized, mono-center Phase I/II study in subjects with IDH-wildtype WHO grade III / IV glioma at first relapse.
- Trial name
- GLIOMOON (NCT03779230)
- Testing
- L19TNF
- Where
- 3 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- Philogen S.p.A.
Astrocytoma, Glioblastoma
CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects…
- Trial name
- NCT04047303
- Testing
- CC-90010
- Where
- 4 sites in United States, Spain
- Volunteers
- 20 people
- Sponsor
- Celgene
Malignant Glioma, Glioblastoma Multiforme
Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
This study seeks to evaluate the tolerability, pharmacokinetics (PK), efficacy, and safety of ABT-414 in Japanese participants with newly diagnosed and recurrent, World Health Organization (WHO) grade III or IV malignant glioma.
- Trial name
- NCT02590263
- Testing
- Whole Brain Radiation, Temozolomide, ABT-414
- Where
- 22 sites in Japan
- Volunteers
- 53 people
- Sponsor
- AbbVie
Glioma
A Phase 2 Study of HX301 in Patients with High-grade Giloma
The study will include a dose-escalation and dose-expansion component to establish the recommended Phase 2 dose (RP2D) for HX301 in combination with Temozolomide and to evaluate the preliminary antitumor activity of HX301.HX301…
- Trial name
- NCT06703255
- Testing
- HX301+/Temozolomide
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
High Grade Glioma, Astrocytoma
Study of Olutasidenib and Temozolomide in HGG
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation.
- Conditions
- High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
- Trial name
- NCT06161974
- Testing
- Olutasidenib + TMZ
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 60 people
- Sponsor
- Rigel Pharmaceuticals